# EDGAR Filing Document

**Accession Number:** 0002023538
**File Stem:** 0001193125-25-321149
**Filing Date:** 2025-12
**Character Count:** 10872
**Document Hash:** ad95d14fa0bd42c406b7e13662a448e9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-321149.hdr.sgml**: 20251216

**ACCESSION NUMBER**: 0001193125-25-321149

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251212

**FILED AS OF DATE**: 20251216

**DATE AS OF CHANGE**: 20251216

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Nemec Sarah
- **CENTRAL INDEX KEY:** 0002023538

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39988
- **FILM NUMBER:** 251576430

**MAIL ADDRESS:**
- **STREET 1:** C/O BOLT BIOTHERAPEUTICS, INC.
- **STREET 2:** 900 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bolt Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001641281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472804636
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 900 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 650-665-9295

**MAIL ADDRESS:**
- **STREET 1:** 900 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bolt Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20150504

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Nemec Sarah<br><sub>(Last) (First) (Middle)</sub><br>900 CHESAPEAKE DRIVE<br><sub>(Street)</sub><br>REDWOOD CITY, CA 94063<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-12 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Senior VP, Finance and PAO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Bolt Biotherapeutics, Inc. [ BOLT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (Right to Buy) | $5.44 | 2025-12-12 |  | A |  | 1236 |  | <sup>(1)</sup> | 2030-09-02 | Common Stock | 1236 | <sup>(2)</sup> | 1236 | D |  |
| Employee Stock Option (Right to Buy) | $86.80 | 2025-12-12 |  | D |  |  | 1236 | <sup>(1)</sup> | 2030-09-02 | Common Stock | 1236 | <sup>(2)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $5.44 | 2025-12-12 |  | A |  | 375 |  | <sup>(1)</sup> | 2031-02-03 | Common Stock | 375 | <sup>(3)</sup> | 375 | D |  |
| Employee Stock Option (Right to Buy) | $400.00 | 2025-12-12 |  | D |  |  | 375 | <sup>(1)</sup> | 2031-02-03 | Common Stock | 375 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $5.44 | 2025-12-12 |  | A |  | 600 |  | <sup>(1)</sup> | 2031-12-21 | Common Stock | 600 | <sup>(4)</sup> | 600 | D |  |
| Employee Stock Option (Right to Buy) | $90.20 | 2025-12-12 |  | D |  |  | 600 | <sup>(1)</sup> | 2031-12-21 | Common Stock | 600 | <sup>(4)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $5.44 | 2025-12-12 |  | A |  | 2199 |  | <sup>(1)</sup> | 2032-02-17 | Common Stock | 2199 | <sup>(5)</sup> | 2199 | D |  |
| Employee Stock Option (Right to Buy) | $61.60 | 2025-12-12 |  | D |  |  | 2199 | <sup>(1)</sup> | 2032-02-17 | Common Stock | 2199 | <sup>(5)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $5.44 | 2025-12-12 |  | A |  | 6699 |  | <sup>(6)</sup> | 2033-01-18 | Common Stock | 6699 | <sup>(7)</sup> | 6699 | D |  |
| Employee Stock Option (Right to Buy) | $27.80 | 2025-12-12 |  | D |  |  | 6699 | <sup>(6)</sup> | 2033-01-18 | Common Stock | 6699 | <sup>(7)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $5.44 | 2025-12-12 |  | A |  | 1589 |  | <sup>(8)</sup> | 2034-03-03 | Common Stock | 1589 | <sup>(9)</sup> | 1589 | D |  |
| Employee Stock Option (Right to Buy) | $25.40 | 2025-12-12 |  | D |  |  | 1589 | <sup>(8)</sup> | 2034-03-03 | Common Stock | 1589 | <sup>(9)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $5.44 | 2025-12-12 |  | A |  | 2499 |  | <sup>(10)</sup> | 2034-07-22 | Common Stock | 2499 | <sup>(11)</sup> | 2499 | D |  |
| Employee Stock Option (Right to Buy) | $14.602 | 2025-12-12 |  | D |  |  | 2499 | <sup>(10)</sup> | 2034-07-22 | Common Stock | 2499 | <sup>(11)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $5.44 | 2025-12-12 |  | A |  | 4499 |  | <sup>(1)</sup> | 2034-07-22 | Common Stock | 4499 | <sup>(11)</sup> | 4499 | D |  |
| Employee Stock Option (Right to Buy) | $14.602 | 2025-12-12 |  | D |  |  | 4499 | <sup>(1)</sup> | 2034-07-22 | Common Stock | 4499 | <sup>(11)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $5.44 | 2025-12-12 |  | A |  | 11299 |  | <sup>(12)</sup> | 2035-04-30 | Common Stock | 11299 | <sup>(13)</sup> | 11299 | D |  |
| Employee Stock Option (Right to Buy) | $7.02 | 2025-12-12 |  | D |  |  | 11299 | <sup>(12)</sup> | 2035-04-30 | Common Stock | 11299 | <sup>(13)</sup> | 0 | D |  |

---

### Footnotes:

(1) The option is fully vested and exercisable.

(2) The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price.

(3) The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price.

(4) The reporting person agreed to cancellation of an option granted on December 22, 2021, in exchange for a new option having a lower exercise price.

(5) The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price.

(6) For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023.

(7) The reporting person agreed to cancellation of an option granted on January 19, 2023, in exchange for a new option having a lower exercise price.

(8) For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024.

(9) The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price.

(10) For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024.

(11) The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price.

(12) For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025.

(13) The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.

**Signature:** /s/ William P. Quinn, Attorney-in-Fact  
**Date:** 2025-12-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**